Navigation Links
Bacteria could make new library of cancer drugs that are too complex to create artificially

Researchers at the University of Warwick are examining a way of using bacteria to manufacture a new suite of potential anti-cancer drugs that are difficult to create synthetically on a lab bench.

The bacterium Streptomyces coelicolor naturally produce antibiotics called prodiginines.

This group of antibiotics has stimulated much recent interest as they can be used to target and kill cancer cells. A synthetic prodiginine analogue called GX15-070 is currently in phase 1 and 2 cancer treatment trials. However, analogues of other prodiginines, such as streptorubin B, could be even more powerful anti cancer tools, but they cannot currently be easily synthetically produced on a lab bench.

Professor Greg Challis and colleagues in the Chemistry Department of the University of Warwick have looked at the enzymes controlling the process that allows the bacterium Streptomyces coelicolor to create streptorubin B and have gained a clear understanding of which are the key enzymes that act at particular steps of that process. By manipulation of the enzyme content of the bacteria, they aim to produce a range of different compounds based closely on the form of streptorubin B normally formed by the bacteria. Some of these analogues of streptorubin B could provide the basis for developing useful new anti cancer drugs.

Professor Challis said:

"This approach combines the strengths of conventional organic synthesis, with the synthetic power of biology, to assemble complex and synthetically difficult structures. It could be particularly valuable for generating analogues of streptorubin B with all the promise that holds for the development of new anti cancer drugs"
'"/>

Source:University of Warwick


Page: 1

Related biology news :

1. Bacteria collection sheds light on urinary tract infections
2. Solution to Pollution: New Bacteria Eats Toxic Waste
3. The Bacterias guide to survival
4. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
5. Bacterial genome sheds light on synthesizing cancer-fighting compounds
6. Where Bacteria Get Their Genes
7. Bacteria feed on smelly breath (and feet)
8. New insight into autoimmune disease: Bacterial infections promote recognition of self-glycolipids
9. Bacteria use hosts immune response to their competitive advantage
10. Say what? Bacterial conversation stoppers
11. Bacteria are key to green plastics, drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/22/2017)... , March 21, 2017 Optimove ... used by retailers such as 1-800-Flowers and AdoreMe, ... — Product Recommendations and Replenishment. Using Optimove,s machine learning ... personalized product and replenishment recommendations to their customers ... on predictions of customer intent drawn from a ...
(Date:3/13/2017)... -- Future of security: Biometric Face Matching software  ... ... Face Matching enables to match face pictures against each other or against large ... Identification Systems) ... is the fastest software for biometric Face Matching on the market. The speed ...
(Date:3/6/2017)... MATEO, Calif. , March 6, 2017 /PRNewswire/ ... marketing and sales technology, today announced Predictive Sales ... solution for infusing actionable sales intelligence into Salesforce. ... to automatically enable their sales organizations with deep ... messages that allow for intelligent engagement. Predictive Sales ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... ... March 28, 2017 , ... ... release of LabKey’s newest software solution, LabKey Biologics . Built in collaboration ... and biotech organizations, LabKey Biologics provides drug research teams tools for biological entity ...
(Date:3/28/2017)... 28, 2017 Focus is ... sector due to the scientifically intensive operations of ... agricultural, environmental, and industrial. In today,s pre-market research, Stock-Callers.com ... Inc. (NASDAQ: PTLA), OvaScience Inc. (NASDAQ: OVAS), Ocera ... (NASDAQ: OCUL ). Learn more about ...
(Date:3/28/2017)... 28, 2017 /PRNewswire/ -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: ... compelling safety and clinical data from its phase 1/2 tendon ... hair follicle-derived fibroblasts (RCT-01) as a treatment for Achilles tendinosis. ... ... safety profile at 6 months and showed no serious adverse ...
(Date:3/28/2017)... ... March 28, 2017 , ... Executive search firm, ... Avomeen Analytical Services. Harvill is a distinguished life sciences expert with a proven ... a leader in a wide range of services related to laboratory testing and ...
Breaking Biology Technology: